Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABBV AbbVie	$183.92 -0.7%	$185.28	$163.52 ▼ $218.66	$327.31B	0.5	6.24 million shs	5.16 million shs
MRK Merck & Co., Inc.	$80.15 +1.4%	$78.91	$73.31 ▼ $134.63	$198.52B	0.38	13.06 million shs	18.55 million shs
PFE Pfizer	$24.04 +0.3%	$23.30	$20.92 ▼ $31.54	$136.28B	0.57	41.30 million shs	31.91 million shs
XLV Health Care Select Sector SPDR Fund	$132.16 -0.3%	$134.36	$127.35 ▼ $159.64	$34.15B	0.64	8.58 million shs	14.18 million shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABBV AbbVie	-0.67%	-3.66%	+0.23%	-8.55%	+7.94%
MRK Merck & Co., Inc.	+1.14%	-1.01%	+3.30%	-8.80%	-38.69%
PFE Pfizer	+0.30%	-1.46%	+3.03%	-5.95%	-13.34%
XLV Health Care Select Sector SPDR Fund	-0.33%	-2.62%	+1.40%	-9.02%	-9.98%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABBV AbbVie	4.9279 of 5 stars	3.4	5.0	4.2	3.9	2.8	2.5	1.3
MRK Merck & Co., Inc.	4.9962 of 5 stars	3.2	5.0	5.0	3.9	3.0	2.5	3.8
PFE Pfizer	4.8605 of 5 stars	2.3	4.0	4.2	4.3	2.3	1.7	3.1
XLV Health Care Select Sector SPDR Fund	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABBV AbbVie	2.81	Moderate Buy	$211.29	14.88% Upside
MRK Merck & Co., Inc.	2.43	Hold	$109.19	36.23% Upside
PFE Pfizer	2.53	Moderate Buy	$29.17	21.33% Upside
XLV Health Care Select Sector SPDR Fund	2.69	Moderate Buy	$132.16	N/A

Current Analyst Ratings Breakdown

Latest ABBV, MRK, PFE, and XLV Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/11/2025	ABBV AbbVie	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Hold	$205.00
6/9/2025	ABBV AbbVie	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Hold	$204.00
5/20/2025	MRK Merck & Co., Inc.	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Cautious
5/14/2025	ABBV AbbVie	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$210.00 ➝ $205.00
5/14/2025	MRK Merck & Co., Inc.	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$115.00 ➝ $84.00
5/8/2025	ABBV AbbVie	BNP Paribas Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
4/30/2025	PFE Pfizer	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$24.00 ➝ $25.00
4/29/2025	ABBV AbbVie	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$214.00 ➝ $216.00
4/28/2025	ABBV AbbVie	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$204.00 ➝ $205.00
4/28/2025	ABBV AbbVie	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$241.00 ➝ $250.00
4/22/2025	ABBV AbbVie	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$210.00

(Data available from 6/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABBV AbbVie	$56.33B	5.77	$14.82 per share	12.41	$1.90 per share	96.80
MRK Merck & Co., Inc.	$64.17B	3.14	$9.60 per share	8.35	$18.33 per share	4.37
PFE Pfizer	$63.63B	2.15	$4.38 per share	5.49	$15.62 per share	1.54
XLV Health Care Select Sector SPDR Fund	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABBV AbbVie	$4.28B	$2.35	78.26	13.16	1.23	7.31%	412.03%	13.11%	7/24/2025 (Estimated)
MRK Merck & Co., Inc.	$17.12B	$6.87	11.67	8.10	0.82	27.27%	43.23%	17.11%	7/29/2025 (Estimated)
PFE Pfizer	$8.03B	$1.38	17.42	7.93	0.87	12.62%	20.33%	8.53%	7/29/2025 (Estimated)
XLV Health Care Select Sector SPDR Fund	N/A	N/A	27.62	∞	N/A	N/A	N/A	N/A	N/A

Latest ABBV, MRK, PFE, and XLV Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
4/29/2025	Q1 2025	PFE Pfizer	$0.67	$0.92	+$0.25	$0.52	$14.43 billion	$13.72 billion
4/25/2025	Q1 2025	ABBV AbbVie	$2.40	$2.46	+$0.06	$0.72	$12.91 billion	$13.34 billion
4/24/2025	Q1 2025	MRK Merck & Co., Inc.	$2.16	$2.22	+$0.06	$2.01	$15.59 billion	$15.53 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABBV AbbVie	$6.56	3.57%	N/A	279.15%	53 Years
MRK Merck & Co., Inc.	$3.24	4.04%	N/A	47.16%	14 Years
PFE Pfizer	$1.72	7.15%	N/A	124.64%	16 Years
XLV Health Care Select Sector SPDR Fund	$2.34	1.77%	N/A	N/A	N/A

Latest ABBV, MRK, PFE, and XLV Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
6/20/2025	ABBV AbbVie	quarterly	$1.64	3.54%	7/15/2025	7/15/2025	8/15/2025
5/27/2025	MRK Merck & Co., Inc.	quarterly	$0.81	4.18%	6/16/2025	6/16/2025	7/8/2025
4/23/2025	PFE Pfizer	quarterly	$0.43	7.69%	5/9/2025	5/9/2025	6/13/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABBV AbbVie	44.14	0.76	0.64
MRK Merck & Co., Inc.	0.69	1.41	1.16
PFE Pfizer	0.64	1.26	0.96
XLV Health Care Select Sector SPDR Fund	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABBV AbbVie	70.23%
MRK Merck & Co., Inc.	76.07%
PFE Pfizer	68.36%
XLV Health Care Select Sector SPDR Fund	N/A

Insider Ownership

Company	Insider Ownership
ABBV AbbVie	0.08%
MRK Merck & Co., Inc.	0.09%
PFE Pfizer	0.06%
XLV Health Care Select Sector SPDR Fund	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABBV AbbVie	55,000	1.77 billion	1.76 billion	Optionable
MRK Merck & Co., Inc.	75,000	2.51 billion	2.51 billion	Optionable
PFE Pfizer	81,000	5.69 billion	5.68 billion	Optionable
XLV Health Care Select Sector SPDR Fund	N/A	258.42 million	N/A	Not Optionable

ABBV, MRK, PFE, and XLV Headlines

Recent News About These Companies

UnitedHealth, CVS Among Major Insurers To Fast-Track Prior Authorizations: Will It Cut Profits Even More?

June 23 at 12:40 PM | benzinga.com

Short bets on S&P 500 Healthcare sector ease in May; MRNA stays most shorted stock

June 13, 2025 | msn.com

I've never seen a setup this negative for health care job growth, says Bancreek's Pachman

June 12, 2025 | youtube.com

Understanding XLV: A Sector ETF Focused On U.S. Healthcare Giants

June 12, 2025 | seekingalpha.com

Should You Invest in the Health Care Select Sector SPDR ETF (XLV)?

June 11, 2025 | zacks.com

6 ETFs to Invest in June

June 6, 2025 | zacks.com

The HealthCare Sector: A Look At Sector Earnings Trends

June 2, 2025 | seekingalpha.com

Healthcare Stocks Are So Bad, They’re Good. What to Buy Now.

May 23, 2025 | msn.com

Palantir Soars 500% In A Year While UnitedHealth Tanks 40% — Tech Leaves Healthcare In The Dust

May 15, 2025 | benzinga.com

Healthcare ETFs Slide as UnitedHealth Plunges

May 13, 2025 | finance.yahoo.com

Top Analyst-Rated Healthcare Stocks to Watch Now (XLV)

May 11, 2025 | marketbeat.com

SPDR Health Care Select Sector (XLV)

May 11, 2025 | uk.investing.com

Healthcare stocks that could be poised for a rebound

May 9, 2025 | msn.com

Upbeat April Jobs Data Put Focus on 3 Sector ETFs & Stocks

May 7, 2025 | zacks.com

Top 3 Sectors Where Valuations Are Most Below Market Levels (XLV)

May 6, 2025 | marketbeat.com

Healthcare sector flexes earnings muscle, but top-line cracks show

May 3, 2025 | msn.com

Invest in These ETFs to Prepare Your Portfolio for a Recession

May 3, 2025 | fool.com

Is Healthcare Losing the Status of Safe Haven? ETFs in Focus

April 30, 2025 | zacks.com

Health Care Sector In 2025: Buy Abbott Labs

April 28, 2025 | forbes.com

Buy Healthcare Stocks Despite RFK Jr., Tariffs, and UnitedHealth

April 25, 2025 | msn.com

5 Sector ETFs Set for Q1 Earnings Growth Amid Tariff Woes

April 11, 2025 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABBV, MRK, PFE, and XLV Company Descriptions

AbbVie NYSE:ABBV

$183.92 -1.38 (-0.74%)

Closing price 06/23/2025 03:59 PM Eastern

Extended Trading

$185.08 +1.16 (+0.63%)

As of 06/23/2025 07:58 PM Eastern

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Merck & Co., Inc. NYSE:MRK

$80.15 +1.09 (+1.38%)

Closing price 06/23/2025 03:59 PM Eastern

Extended Trading

$80.34 +0.19 (+0.24%)

As of 06/23/2025 07:59 PM Eastern

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Pfizer NYSE:PFE

$24.04 +0.07 (+0.29%)

Closing price 06/23/2025 03:59 PM Eastern

Extended Trading

$24.04 0.00 (-0.02%)

As of 06/23/2025 07:59 PM Eastern

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Health Care Select Sector SPDR Fund NYSEARCA:XLV

$132.16 -0.44 (-0.33%)

Closing price 06/23/2025 04:10 PM Eastern

Extended Trading

$132.45 +0.29 (+0.22%)

As of 06/23/2025 08:00 PM Eastern

Health Care Select Sector SPDR Fund (the Fund) seeks to closely match the returns and characteristics of the S&P Health Care Select Sector Index (the Index). The companies included in the Index are selected on the basis of general industry classification from a universe of companies defined by the Standard & Poor's 500 Composite Stock Index (S&P 500). The Health Care Select Sector Index includes companies from the industries, such as pharmaceuticals, healthcare providers and services, healthcare equipment and supplies, biotechnology, life sciences tools and services, and healthcare technology. Under normal market conditions, the Fund generally invests substantially all, but at least 95%, of its total assets in the securities comprising the Index. State Street Global Advisors acts as the Fund's investment manager.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time